about
Imaging VCAM-1 as an indicator of treatment efficacy in metastatic ovarian cancerPharmacodynamic model for chemotherapy-induced anemia in rats.Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group.A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activityHematological toxicity of carboplatin for gynecological cancer according to body mass index.A pharmacologically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer.Co-delivery of carboplatin and paclitaxel via cross-linked multilamellar liposomes for ovarian cancer treatment.Comparative Pharmacokinetics and Allometric Scaling of Carboplatin in Different Avian SpeciesHuman red blood cells: rheological aspects, uptake, and release of cytotoxic drugs.In vitro anticancer activity of cis-diammineplatinum(II) complexes with β-diketonate leaving group ligandsPharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support.Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.Renal pelvic hemorrhage and acute renal failure associated with carboplatin therapyMechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.Impact of exposure to tobacco smoke, arsenic, and phthalates on locally advanced cervical cancer treatment-preliminary resultsSynthetic methods for the preparation of platinum anticancer complexes.Antibody-targeted nanoparticles for cancer therapy.A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer.Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.Thinking outside the shunt-sterile CSF malabsorption in pilocytic astrocytomas: case series and review of the literature.Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors.Tandem therapy for retinoblastoma: immunotherapy and chemotherapy enhance cytotoxicity on retinoblastoma by increasing apoptosis.Phase I study and clinical pharmacological evaluation of daily oral etoposide combined with carboplatin in patients with lung cancer.A model of hematopoietic stem cell proliferation under the influence of a chemotherapeutic agent in combination with a hematopoietic inducing agent.Pharmacokinetics and toxicity of subcutaneous administration of carboplatin in poloxamer 407 in a rodent model pilot study.Toxicity of high-dose carboplatin: ultrafiltered and not total plasma pharmacokinetics is of clinical relevance.
P2860
Q30413757-AB1F0D65-2426-4288-A188-F18FF3D9A117Q33376775-393D4EBC-E743-410D-BCAF-49488FEC55C7Q33380181-C9586FE1-FEAB-4A70-99A2-80A57ABC7B2AQ33399785-7A03CA45-4382-40B8-942B-757E9BAAE00CQ33421343-9AAD5897-5A2A-4764-875E-D919C438FF03Q33432963-7FF38170-D44E-4EFE-B7C3-630B19622C2BQ33490385-8B32AB3E-53CA-49D9-9029-FDC74A7CE30FQ33742311-C4227AF1-15B6-4555-B092-9D8AB9FB5A72Q35723832-8D10B81D-8452-416A-995B-8D6DB9726E37Q35843499-92BD7857-E175-48F1-BC86-62B56530EF3AQ36032615-E4BD17C8-D713-4F59-93AD-7B054E80AF79Q36138637-087B3528-E27D-4BF8-ABBB-BB53981EA5EBQ36421620-99EB44B2-357F-4571-8A67-C4582B0BC66CQ36468277-4B09ADBB-FC66-4B14-9950-1AB6D7FA5952Q36620291-C5751C8D-7792-4080-88DD-E280D039FE54Q37247308-0B1357CD-92C6-4DA3-99AB-A0AD837443A9Q37722632-981DBDF2-ACA1-4AEB-AA66-BB6FE01F18FDQ37851969-497B9F05-DEA1-421D-A86A-F6235C8E711CQ38706298-002BBE55-D252-4E26-BC1C-B9C61433320BQ38728212-39D6DC71-5BA1-4E3E-9CDB-76E8B0F314BBQ38837538-3FD0072F-ED14-4828-A6A6-E57EF0D71FF4Q38975455-18E882C9-F1CE-42BB-BB20-C18CBB87FE79Q39149552-2A8003CA-3BF2-4D6A-9469-C5582578972AQ40986092-EDB25526-0B2E-4197-9E55-DB45688FEF24Q41887008-05101CEC-CAB6-4C01-8942-399DC474B147Q42699776-05CA100E-8E6D-450C-894D-3F5CD5797AF4Q44046722-2E532A25-4DE5-4787-BE8A-F632AB7FFAD1
P2860
description
1991 nî lūn-bûn
@nan
1991 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Clinical pharmacokinetics of carboplatin.
@ast
Clinical pharmacokinetics of carboplatin.
@en
type
label
Clinical pharmacokinetics of carboplatin.
@ast
Clinical pharmacokinetics of carboplatin.
@en
prefLabel
Clinical pharmacokinetics of carboplatin.
@ast
Clinical pharmacokinetics of carboplatin.
@en
P1476
Clinical pharmacokinetics of carboplatin.
@en
P2093
van der Vijgh WJ
P304
P356
10.2165/00003088-199121040-00002
P577
1991-10-01T00:00:00Z
P6179
1047951045